Univest
Univest
  • Markets

Dr. Agarwal’s Health Care Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

  • July 3, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Dr. Agarwal's Health Care Q1 Results FY27

Dr. Agarwal’s Health Care CMP Rs.474. Q1 FY27E revenue Rs.565-650 Cr. PAT estimate Rs.39-50 Cr. 12-month target Rs.551-613.

Dr. Agarwal’s Health Care Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Dr. Agarwal’s Health Care shares trading at Rs.474 against a market capitalisation of Rs.15,099 Cr and a price-to-earnings multiple of 89.9. As an industrials and capital goods name on the NSE and BSE, Dr. Agarwal’s Health Care enters the Dr. Agarwal’s Health Care Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

This Dr. Agarwal’s Health Care Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.501 Cr revenue and Rs.38 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.

Get Free Investment Predictions and Dr. Agarwal’s Health Care Research at Univest

Table of Contents

Toggle
  • About Dr. Agarwal’s Health Care
  • Dr. Agarwal’s Health Care Q1 FY27 Estimates
  • Key Catalysts to Watch
    • 1. Order Book Execution
    • 2. Capex Revival in User Industries
    • 3. Operating Leverage
  • Key Risks to the Dr. Agarwal’s Health Care Q1 Results FY27 Outlook
  • Q4 FY26 Performance Context for the Dr. Agarwal’s Health Care Q1 Results FY27 Print
  • Technical Analysis Ahead of Dr. Agarwal’s Health Care Q1 Results FY27
  • Share Price Target Based on the Dr. Agarwal’s Health Care Q1 Results FY27 Outlook
    • 3-6 Month Target
    • 12-Month Target
    • FY27-28 Outlook
  • What to Watch in the Dr. Agarwal’s Health Care Q1 Results FY27 Print
  • Conclusion on Dr. Agarwal’s Health Care Q1 Results FY27
  • FAQs on Dr. Agarwal’s Health Care Q1 Results FY27
    • When are Dr. Agarwal’s Health Care Q1 FY27 results expected?
    • What is the Dr. Agarwal’s Health Care Q1 FY27 revenue estimate?
    • What is the Dr. Agarwal’s Health Care share price target?
    • Is Dr. Agarwal’s Health Care a good buy before Q1 FY27 results?
    • What should investors watch in Dr. Agarwal’s Health Care’s Q1 FY27 results?
    • Where can I track Dr. Agarwal’s Health Care share price live?

About Dr. Agarwal’s Health Care

Dr. Agarwal’s Health Care (NSE: AGARWALEYE) operates in the industrials and capital goods space and is tracked on Univest under its NSE and BSE listings. Ahead of the Dr. Agarwal’s Health Care Q1 Results FY27 print, the company’s Q4 FY26 base shows revenue of Rs.577 Cr and net profit of Rs.50 Cr, forming the base against which the Dr. Agarwal’s Health Care Q1 Results FY27 estimates in this article are built. This Dr. Agarwal’s Health Care Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Dr. Agarwal’s Health Care Q1 FY27 Estimates

Metric Q1 FY27E (Range) Q1 FY26 Actual YoY Growth
Revenue (Rs. Cr) 565-650 501 +21.2%
Net Profit / PAT (Rs. Cr) 39-50 38 +17.4%
Results Date July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate) Rs.551-613

Univest, a SEBI-Registered Investment Advisor, Tracks Dr. Agarwal’s Health Care Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Order Book Execution

Healthy order book execution translating into revenue recognition for the quarter is one of the primary variables that analysts are tracking ahead of Dr. Agarwal’s Health Care’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Dr. Agarwal’s Health Care share price target or faces renewed pressure.

2. Capex Revival in User Industries

Capex revival in core user industries supporting fresh order inflows is one of the primary variables that analysts are tracking ahead of Dr. Agarwal’s Health Care’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Dr. Agarwal’s Health Care share price target or faces renewed pressure.

3. Operating Leverage

Operating leverage on higher volumes aiding margin expansion versus last year is one of the primary variables that analysts are tracking ahead of Dr. Agarwal’s Health Care’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Dr. Agarwal’s Health Care share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Dr. Agarwal’s Health Care’s live price and Q1 FY27 result updates.

Key Risks to the Dr. Agarwal’s Health Care Q1 Results FY27 Outlook

  • Order execution delays pushing revenue recognition to later quarters.
  • Raw material and input cost inflation pressuring margins.
  • Slower capex recovery in key end-user industries affecting order inflows.

Q4 FY26 Performance Context for the Dr. Agarwal’s Health Care Q1 Results FY27 Print

Dr. Agarwal’s Health Care closed Q4 FY26 with revenue of Rs.577 Cr and net profit of Rs.50 Cr, a year-on-year revenue change of +21.2% and PAT change of +17.4%. This base underpins the Dr. Agarwal’s Health Care Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Dr. Agarwal’s Health Care Q1 Results FY27 commentary once reported.

Technical Analysis Ahead of Dr. Agarwal’s Health Care Q1 Results FY27

Dr. Agarwal’s Health Care shares last traded at Rs.474. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Dr. Agarwal’s Health Care Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Dr. Agarwal’s Health Care Q1 Results FY27 trailing-growth framework points to a range of Rs.490-528 for Dr. Agarwal’s Health Care, contingent on the Dr. Agarwal’s Health Care Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Dr. Agarwal’s Health Care Q1 Results FY27 view for Dr. Agarwal’s Health Care works out to Rs.551-613, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into Dr. Agarwal’s Health Care Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Dr. Agarwal’s Health Care Q1 Results FY27 analysis would put Dr. Agarwal’s Health Care in a Rs.621-707 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Dr. Agarwal’s Health Care Q1 Results FY27 Print

  • Revenue and PAT versus the Dr. Agarwal’s Health Care Q1 Results FY27 estimate range in this preview.
  • Management commentary on FY27 growth guidance and margin trajectory relevant to the Dr. Agarwal’s Health Care Q1 Results FY27 narrative.
  • Healthy order book execution translating into revenue recognition for the quarter
  • Order execution delays pushing revenue recognition to later quarters

Conclusion on Dr. Agarwal’s Health Care Q1 Results FY27

Dr. Agarwal’s Health Care enters the Q1 FY27 results season trading at Rs.474, with the 12-month Uniresearch target range of Rs.551-613 reflecting a tracking with a constructive bias stance. Investors tracking the Dr. Agarwal’s Health Care Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Dr. Agarwal’s Health Care Q1 Results FY27

When are Dr. Agarwal’s Health Care Q1 FY27 results expected?

Ans. Dr. Agarwal’s Health Care’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Dr. Agarwal’s Health Care Q1 FY27 revenue estimate?

Ans. The Uniresearch trailing-growth estimate for Dr. Agarwal’s Health Care’s Q1 FY27 revenue is Rs.565-650 Cr, based on the Q1 FY26 base of Rs.501 Cr.

What is the Dr. Agarwal’s Health Care share price target?

Ans. The 12-month Uniresearch estimate for Dr. Agarwal’s Health Care share price target is Rs.551-613, based on trailing growth and current valuation multiples.

Is Dr. Agarwal’s Health Care a good buy before Q1 FY27 results?

Ans. Dr. Agarwal’s Health Care is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Dr. Agarwal’s Health Care’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and healthy order book execution translating into revenue recognition for the quarter.

Where can I track Dr. Agarwal’s Health Care share price live?

Ans. Dr. Agarwal’s Health Care share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply